Schizophrenia Research-Cognition最新文献

{"title":"Use of reference markers in the speech of people with schizophrenia spectrum disorders: Evidence from two referential communication tasks manipulating common ground with the interaction partner","authors":"Amélie M. Achim ,&nbsp;Dominique Knutsen ,&nbsp;Marc-André Roy ,&nbsp;Souleymane Gadio ,&nbsp;Marion Fossard","doi":"10.1016/j.scog.2024.100343","DOIUrl":"10.1016/j.scog.2024.100343","url":null,"abstract":"<div><h3>Introduction</h3><div>People with schizophrenia spectrum disorders present with language dysfunctions, yet we know little about their use of reference markers (indefinite markers, definite markers, pronouns or names), a fundamental aspect of efficient speech production.</div></div><div><h3>Methods</h3><div>Twenty-five (25) participants with a recent-onset schizophrenia spectrum disorder (SZ) and 25 healthy controls (HC) completed two referential communication tasks. The tasks involved presenting to an interaction partner a series of movie characters (character identification task) and movie scenes composed of six images (narration task). A manipulation was introduced such that half of the movies could be considered as Likely-Known by the interaction partner, whereas the other half was Likely-Unknown. The analyses focused on the reference markers used to present the movie characters during the tasks.</div></div><div><h3>Results</h3><div>During the character identification task, the SZ group used fewer names and more pronouns than the HC. During the narration task, the SZ group used fewer names and more definite references when initially introducing the main story characters, while no group effect emerged for subsequent mentions of the characters. The observed effects of conditions were generally present across both groups, except for a lesser adjustment in the use of definite markers when introducing the story characters.</div></div><div><h3>Conclusions</h3><div>While some group differences emerged, people with SZ were generally sensitive to the manipulation regarding their interaction partner's likely knowledge of the characters. A better understanding of the conditions in which speech production is affected in SZ could help promote more efficient communication.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100343"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender differences in cognitive performance among young adults with first-episode schizophrenia in China","authors":"NingJing Sang ,&nbsp;YiMin Fan ,&nbsp;HaiYing Chen ,&nbsp;HuiRu Cui ,&nbsp;YanYan Wei ,&nbsp;XiaoChen Tang ,&nbsp;LiHua Xu ,&nbsp;Yi Mei ,&nbsp;JiJun Wang ,&nbsp;TianHong Zhang","doi":"10.1016/j.scog.2025.100353","DOIUrl":"10.1016/j.scog.2025.100353","url":null,"abstract":"<div><h3>Background</h3><div>Individuals with schizophrenia exhibit distinctive patterns of cognitive impairments, which pose difficulties in patients' everyday functionality and reduce patients' quality of life. Previous research suggests that many demographic variables, such as gender and age, influence the cognitive performance profiles of schizophrenia patients; however, the gender differences in neurocognitive dysfunction among first-episode schizophrenia (FES) patients remain less clear.</div></div><div><h3>Methods</h3><div>In this cross-sectional study, we compared the cognitive performance of FES patients to that of healthy controls (HC), with a specific focus on gender differences within the Chinese population aged under 35 years. Cognitive performance was assessed using the raw scores from the MATRICS Consensus Cognitive Battery (MCCB).</div></div><div><h3>Results</h3><div>FES patients show lower overall cognitive impairment across all MCCB domains compared to HCs. Significant sex effects were observed: females outperformed males in aspects of speed of processing and verbal learning in FES, while males outperformed females in parts of working memory and reasoning and problem solving among HC patients. In both FES and HC groups, females exceeded males in visual learning. Moreover, employing a three-way multivariate analysis of variance (MANOVA) displayed interaction effects between gender and clinical diagnosis in areas of speed of processing and verbal learning.</div></div><div><h3>Conclusions</h3><div>This suggests that schizophrenia and biological sex may jointly influence performance in these domains, emphasizing the need for early intervention and gender-sensitive approaches to address cognitive deficits in schizophrenia.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100353"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of cariprazine on attention and quality of life in patients with predominant negative symptoms of schizophrenia: A post-hoc analysis","authors":"Oloruntoba J. Oluboka ,&nbsp;Andrea Bardell ,&nbsp;Howard C. Margolese ,&nbsp;Philip G. Tibbo ,&nbsp;Lisa Buchy ,&nbsp;Christine Di Cresce ,&nbsp;Jun Yu ,&nbsp;Roger S. McIntyre","doi":"10.1016/j.scog.2025.100355","DOIUrl":"10.1016/j.scog.2025.100355","url":null,"abstract":"<div><h3>Background</h3><div>Cariprazine, a potent dopamine D₃-preferring D₃/D₂ receptor partial agonist, has demonstrated benefits on negative symptoms among patients with schizophrenia. Secondary endpoint and post-hoc analyses have also suggested a benefit of cariprazine on quality of life (QoL) and attention.</div></div><div><h3>Methods</h3><div>Data for this <em>post-hoc</em> analysis were pooled from two 6-week, placebo-controlled phase 3 trials evaluating cariprazine among patients with acute exacerbations of schizophrenia. One study included an aripiprazole active-control arm for assay sensitivity.</div><div>Two populations were analyzed: pooled intention-to-treat (ITT) population (<em>N</em> = 1043), and the pooled subgroup with predominant negative symptoms (PNS, <em>n</em> = 215), as defined by the Positive and Negative Syndrome Scale (PANSS) subscale and item cut-off criteria at baseline. Analyses of interest were: Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) total score; Cognitive Drug Research (CDR) power of attention (PoA), and continuity of attention (CoA).</div></div><div><h3>Results</h3><div>Among study completers, cariprazine and aripiprazole were associated with significant SQLS-R4 improvements in the ITT and PNS populations. Differences in CDR-PoA scores were significant for cariprazine vs. placebo in the ITT and PNS populations, but not for aripiprazole in the ITT or PNS analyses. Differences in CDR-CoA scores were significant for cariprazine vs. placebo in the ITT and PNS analyses; and was significant for aripiprazole vs. placebo in the PNS analysis, but not in the ITT analysis.</div></div><div><h3>Conclusions</h3><div>This post-hoc analysis suggests that cariprazine may be associated with beneficial effects on measures of attention and QoL among patients with schizophrenia, and these effects could be more pronounced among individuals with PNS.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100355"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social cognitive training among individuals with schizophrenia: Identifying responders to treatment","authors":"Anja Vaskinn ,&nbsp;André Løvgren ,&nbsp;Ole A. Andreassen ,&nbsp;Kjetil Sundet","doi":"10.1016/j.scog.2025.100350","DOIUrl":"10.1016/j.scog.2025.100350","url":null,"abstract":"<div><div>In this follow-up study of a previous randomized controlled trial of targeted facial affect recognition training among individuals with schizophrenia, reliable change indices (RCIs) were employed to identify responders to treatment. The original study found improved theory of mind at 3-month follow-up. The current study included 15 participants who received the intervention and who completed all three assessment points in the original study. Six of them had RCIs over the cutoff (≥+1.64), indicating that they had a clinically meaningful and statistically reliable improvement in ToM. The responders had significantly higher psychotic symptom level at baseline, but no other group differences between responders and nonresponders were identified. The study found no support for suggested moderators of treatment effect of social cognitive training (sex, education). As no consistently replicated barriers to treatment gains have been identified, we suggest that social cognitive training, where available, should be offered to interested clients.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100350"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The awareness, characterization, and burden of Cognitive Impairment Associated with Schizophrenia (CIAS) in clinical practice: Results from a nationwide survey in Italy","authors":"Antonio Vita ,&nbsp;Stefano Barlati ,&nbsp;Roberto Cavallaro ,&nbsp;Riccardo Cipelli ,&nbsp;Giulio Corrivetti ,&nbsp;Dario Delmonte ,&nbsp;Eleonora Lusito ,&nbsp;Elisabetta Maia ,&nbsp;Maria Michela Marino ,&nbsp;Giuseppe Nicolò ,&nbsp;Paola Rocca ,&nbsp;Silvana Galderisi","doi":"10.1016/j.scog.2025.100352","DOIUrl":"10.1016/j.scog.2025.100352","url":null,"abstract":"<div><h3>Introduction</h3><div>Cognitive Impairment (CIAS) is a core aspect of schizophrenia and one of the main obstacles to clinical and functional recovery in patients. People with CIAS have difficulties with learning and using information in real world. Despite its well-recognized role, it is not yet a diagnostic criterion in DSM-5 and ICD system. The effective management of CIAS represents a critical unmet need of schizophrenia treatment.</div></div><div><h3>Methods</h3><div>To evaluate the awareness of CIAS in the Italian landscape, we conducted a quantitative survey on psychiatrists highly specialized in schizophrenia, focused on its awareness, assessment, burden, and treatment.</div></div><div><h3>Results</h3><div>Of 152 participants, 139 (91.4 %) consider CIAS assessment important. The terminology most frequently used to describe CIAS is ‘cognitive impairment’. CIAS is assessed, clinically or with formal tools, in approximately 43 % of patients after stabilisation either during follow-up visits (<em>N</em> = 88, 67.7 %) or during hospital stay (<em>N</em> = 57, 43.8 %). 65 % of evaluated patients are considered affected by CIAS. Formal assessment tools (tests, questionnaires, interviews) are used in about 20 % of the centers. The Mini Mental State Examination (MMSE) (<em>N</em> = 75, 72.1 %) and the Wechsler Adult Intelligence Scale (WAIS) (<em>N</em> = 62, 59.6 %) are the most frequently used tools for CIAS evaluation.</div></div><div><h3>Conclusions</h3><div>The clinical characteristics of the patient, structural barriers like the lack of trained personnel or inadequate economic resources, and organizational problems influence the assessment rate. Despite this awareness, greater effort must be made to overcome the barriers, especially economic and organizational ones, which prevent the assessment and treatment of CIAS from becoming established in routine clinical care.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100352"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143438278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ecological validity in cognitive assessment and treatment","authors":"Kathryn E. Lewandowski","doi":"10.1016/j.scog.2024.100341","DOIUrl":"10.1016/j.scog.2024.100341","url":null,"abstract":"","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100341"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairments in first-episode psychosis patients with attenuated niacin response","authors":"MingLiang Ju ,&nbsp;Bin Long ,&nbsp;YanYan Wei ,&nbsp;XiaoChen Tang ,&nbsp;LiHua Xu ,&nbsp;RanPiao Gan ,&nbsp;HuiRu Cui ,&nbsp;YingYing Tang ,&nbsp;ZhengHui Yi ,&nbsp;HaiChun Liu ,&nbsp;ZiXuan Wang ,&nbsp;Tao Chen ,&nbsp;Jin Gao ,&nbsp;Qiang Hu ,&nbsp;LingYun Zeng ,&nbsp;ChunBo Li ,&nbsp;JiJun Wang ,&nbsp;HuanZhong Liu ,&nbsp;TianHong Zhang","doi":"10.1016/j.scog.2025.100346","DOIUrl":"10.1016/j.scog.2025.100346","url":null,"abstract":"<div><h3>Background</h3><div>Psychosis is a complex brain disorder with diverse biological subtypes influenced by various pathogenic mechanisms, which can affect treatment efficacy. The ANR(Attenuated Niacin Response) subtype is characterized by pronounced negative symptoms and functional impairments, suggesting a distinct clinical profile. However, research on the cognitive characteristics associated with the ANR subtype in drug-naïve first-episode psychosis(FEP) patients remains limited.</div></div><div><h3>Methods</h3><div>This observational study involved 54 FEP patients and 52 healthy controls(HC). Clinical psychopathology was assessed using the Positive and Negative Syndrome Scale(PANSS), while cognitive performance was evaluated through the Chinese version of the MATRICS Consensus Cognitive Battery(MCCB). Additionally, niacin response was measured using aqueous methylnicotinate patches, with responses quantified to classify participants into ANR or normal niacin response (NNR) groups.</div></div><div><h3>Results</h3><div>Among the FEP patients, 25.9 % were classified as having ANR, significantly higher than the 7.7 % in the HC group (<em>χ</em>^<em>2</em> = 6.247, <em>p</em> = 0.012). The ANR group exhibited more severe negative symptoms and higher total PANSS scores compared to the NNR group, with significant differences in cognitive performance on the Trail Making test and the Brief Visuospatial Memory Test-Revised. Correlation analyses revealed a significant positive relationship between overall symptom severity and niacin response, as well as between cognitive performance and niacin response, particularly for the Trail Making and Symbol coding tests.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that the ANR subtype in first-episode psychosis is linked to more severe negative symptoms and cognitive impairments. Targeted assessments and interventions for patients with ANR may improve treatment outcomes and enhance understanding of cognitive dysfunction in psychotic disorders.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100346"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of dual-target rTMS over dorsolateral prefrontal cortex (DLPFC) and cerebellum in the treatment of negative symptoms in first-episode schizophrenia: Protocol for a multicenter, randomized, double-blind, sham-controlled study","authors":"Junjie Wang ,&nbsp;Yanyan Wei ,&nbsp;Qiang Hu ,&nbsp;Yingying Tang ,&nbsp;Hongliang Zhu ,&nbsp;Jijun Wang","doi":"10.1016/j.scog.2024.100339","DOIUrl":"10.1016/j.scog.2024.100339","url":null,"abstract":"<div><h3>Background and objective</h3><div>The dorsolateral prefrontal cortex (DLPFC) - cerebellum circuit has been implicated in the pathogenesis of negative symptoms of schizophrenia (SZ). Both areas are considered separate targets for repetitive transcranial magnetic stimulation (rTMS) treatment, showing potential for improving negative symptoms. However, there is still a lack of research that targets both DLPFC and cerebellum simultaneously. In this study, we will explore the efficacy and safety of dual-target rTMS based on the DLPFC-cerebellum circuit in the treatment of negative symptoms in SZ.</div></div><div><h3>Methods</h3><div>The study is a multicenter randomized, double-blind, and sham-controlled trial. First-episode schizophrenia is treated with adjunctive 1 Hz rTMS to the right DLPFC and intermittent theta burst stimulation (iTBS) to the cerebellum delivered sequentially in 20 sessions (active group) or a sham condition (sham group) along with antipsychotics. Clinical symptoms are assessed using the Positive and Negative Symptom Scale (PANSS) at baseline (T0), at the middle of the TMS intervention (after 10 sessions, T1), at the end of the intervention (after 20 sessions, T2), and at a 4-week follow-up after the intervention concludes (T3). Subjects will undergo magnetic resonance imaging (MRI) scans twice: once at baseline (T0) and again at the end of TMS intervention (T2). Comparisons of improvements in negative symptoms are conducted between the active and sham groups. Alterations in functional connectivity (FC) are also compared between both groups. Pearson or Spearman correlation analysis is performed to estimate the relationship between FC alteration and clinical symptom remission (PANSS negative subscale reduction scores and response rates, etc) depending on whether the data follows a normal distribution. In addition, potential neuroimaging biomarkers based on MRI associated with TMS treatment will be explored.</div></div><div><h3>Discussion</h3><div>Positive results from this double-blind, sham-controlled, randomized study may optimize the TMS treatment strategy for SZ, particularly in managing negative symptoms. Clinicians can select TMS with increased confidence as a safe adjunctive treatment option. Furthermore, the findings of this trial may offer preliminary insights into the potential neuroimaging therapeutic mechanisms of TMS interventions targeting the prefrontal-cerebellar circuit.</div><div>Trial registration: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> <span><span>NCT04853485</span><svg><path></path></svg></span></div><div>Primary sponsor: Jijun WANG (J. Wang), Principal Investigator: <span><span><span>[email protected]</span></span><svg><path></path></svg></span></div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"39 ","pages":"Article 100339"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The implementation and effectiveness of Integrated Psychological Therapy (IPT) in chronic middle-aged inpatients with schizophrenia","authors":"Aikaterini Poulou ,&nbsp;Fotios Anagnostopoulos ,&nbsp;Argiro Vatakis ,&nbsp;Robert C. Mellon ,&nbsp;Daniel R. Mueller","doi":"10.1016/j.scog.2024.100330","DOIUrl":"10.1016/j.scog.2024.100330","url":null,"abstract":"<div><h3>Introduction</h3><div>Cognitive rehabilitation is essential for schizophrenia treatment since it improves function. Moreover, the relationship between cognitive rehabilitation and functioning is significantly affected by negative symptoms and social cognition. Integrated Psychological Therapy (IPT) is a promising approach that integrates interventions in neurocognition, social cognition, and functional level. This study examines IPT's efficacy in chronic middle-aged inpatients.</div></div><div><h3>Methods</h3><div>A randomized controlled study involved 44 individuals with schizophrenia. Twenty-one IPT participants received 50 biweekly sessions and medication, while twenty-three control participants received treatment as usual/supportive therapy and pharmacotherapy. Pre- and post-intervention and six- and twelve-month follow-ups were arranged to assess neurocognition, social perception, psychopathology, and functioning using the Matrics Consensus Cognitive Battery, Social Perception Scale, Positive and Negative Syndrome Scale, and Global Assessment of Functioning.</div></div><div><h3>Results</h3><div>Speed of processing, attention/vigilance, overall composite, and neurocognitive composite scores improved significantly in the IPT group. Social Perception Scale performance improved in all areas after the intervention and persisted for 6 months. Positive, negative, and total psychopathology symptoms decreased significantly post-intervention and at the 12-month follow-up, whereas participants' functioning improved significantly.</div></div><div><h3>Conclusions</h3><div>Middle-aged chronic inpatients with schizophrenia may benefit from IPT in neurocognition, social perception, psychopathology, and functioning. This field of study may provide insight into schizophrenia treatment, hence further research is encouraged.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"39 ","pages":"Article 100330"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2215001324000313/pdfft?md5=573f6f718b25b0f5042295b79275e95f&pid=1-s2.0-S2215001324000313-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the ecological validity of research on social cognition in schizophrenia: A systematic review of the literature","authors":"Alvaro Cavieres,&nbsp;Vanessa Acuña,&nbsp;Marcelo Arancibia,&nbsp;Camila Escobar","doi":"10.1016/j.scog.2024.100333","DOIUrl":"10.1016/j.scog.2024.100333","url":null,"abstract":"<div><h3>Introduction</h3><div>Ecologically valid assessments need to require tasks representative of real, everyday interactions between people in a social environment (i.e., verisimilitude) and to predict aspects of real-life performance in those same interactions (i.e., veridicality). To determine how researchers interested in social cognition among people with schizophrenia currently understand and apply ecological validity in their work, we conducted a systematic review of studies that had the ecological validity of their results as an explicit objective.</div></div><div><h3>Methods</h3><div>We performed the described systematic review following PRISMA guidelines.</div></div><div><h3>Results</h3><div>Of the 18 studies reviewed, only two defined <em>ecological validity</em>, 15 incorporated modifications to improve their verisimilitude, eight proposed analyses to examine their veridicality, and seven aimed to achieve both objectives.</div></div><div><h3>Conclusions</h3><div>Our systematic review suggests that very few published studies on social cognition among people with schizophrenia have explicitly defined <em>ecological validity</em>, and most have focused only on the verisimilitude of the tasks required while neglecting the veridicality of the results.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"39 ","pages":"Article 100333"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}